Volume 10, Number 6—June 2004
Research
Antimicrobial Resistance among Campylobacter Strains, United States, 1997–2001
Table 2
Antimicrobial | % Resistant |
||||||
---|---|---|---|---|---|---|---|
1989-1990 (n = 286)a,b | 1997 (n = 209) | 1998 (n = 297) | 1999 (n = 294) | 2000 (n = 306) | 2001 (n = 365) | Total (n = 1,471) | |
Azithromycinc |
1 |
– |
1 |
3 |
2 |
2 |
2 |
chloramphenicol |
0 |
1 |
1 |
0.3 |
0 |
0 |
0.3 |
Ciprofloxacin |
0 |
12 |
14 |
18 |
14 |
18 |
16 |
Clindamycin |
1 |
1 |
1 |
1 |
1 |
2 |
1 |
Erythromycin |
1 |
1 |
2 |
2 |
1 |
2 |
2 |
Gentamicinc |
0 |
– |
0 |
0 |
0 |
0 |
0 |
nalidixic acid |
1 |
13 |
16 |
20 |
16 |
19 |
17 |
Tetracycline | 42 | 47 | 46 | 46 | 39 | 40 | 43 |
a1989–1990 U.S. sentinel county study used different sampling and laboratory methods (microbroth dilution testing) than NARMS (E-test). However, studies have concluded that broth microdilution and E-test give equivalent results for ciprofloxacin susceptibility testing of Campylobacter (44).
bIn 1989–1990 U.S. county study, only 285 isolates were tested for azithromycin and nalidixic acid susceptibility.
cFor azithromycin and gentamicin, only isolates received between 1998 and 2001 were tested (N = 1,262).
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.